• Piper Sandler led CereVasc’s oversubscribed Series C equity financing, raising $85 million to advance its eShunt system.
• New investors included Johnson & Johnson Innovation (JJDC) and Medtronic; existing backers Bain Capital Life Sciences and Perceptive Xontogeny also participated.
• Funds target completion of the STRIDE pivotal trial in normal pressure hydrocephalus, PMA work for the FDA, operational scale-up, US launch preparations.
• Tom Schnettler joined CereVasc’s board representing the Series C investor group.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Piper Sandler Companies published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606040634PR_NEWS_USPR_____NE75688) on June 04, 2026, and is solely responsible for the information contained therein.